Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EVAX | US
-0.10
-3.79%
Healthcare
Biotechnology
30/06/2024
21/10/2024
2.54
2.66
2.76
2.50
Evaxion Biotech A/S a clinical-stage biotech company engages in developing artificial intelligence-powered immunotherapies for cancers bacterial diseases and viral infections. The company develops EVX-01 a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02 a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03 a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1 EVX-B2 and EVX-V1 which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm Denmark.
View LessLow Market Beta (-0.4 to 0.8)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
48.0%1 month
55.3%3 months
85.4%6 months
78.1%-
3.57
12.06
8.37
0.69
-0.59
63.35
-
-18.80M
14.17M
14.17M
-
-2.97K
-
-
-802.80
0.90
2.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.68
Range1M
0.80
Range3M
1.25
Rel. volume
0.16
Price X volume
27.28K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1368 | 15.04M | 6.79% | n/a | 21.43% |
| Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.47 | 14.99M | -2.63% | n/a | 2.12% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 4.92 | 14.98M | 7.19% | n/a | 10.72% |
| ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.5352 | 14.94M | -0.89% | n/a | 49.00% |
| Cara Therapeutics Inc | CARA | Biotechnology | 0.2656 | 14.57M | 0.19% | n/a | 406.66% |
| Evogene Ltd | EVGN | Biotechnology | 2.58 | 14.44M | 7.50% | n/a | 26.41% |
| IMNN | IMNN | Biotechnology | 0.9925 | 14.29M | 0.71% | n/a | 37.13% |
| Cyclacel Pharmaceuticals Inc | CYCCP | Biotechnology | 7.3 | 13.88M | 0.00% | n/a | 0.50% |
| Tenax Therapeutics Inc | TENX | Biotechnology | 4.05 | 13.81M | 2.53% | n/a | 3.14% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.23 | 13.71M | -2.62% | n/a | 54.59% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.59 | - | Cheaper |
| Ent. to Revenue | 63.35 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 12.06 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 85.42 | - | Par |
| Debt to Equity | 8.37 | -1.23 | Expensive |
| Debt to Assets | 0.69 | 0.25 | Expensive |
| Market Cap | 14.17M | - | Emerging |